December 2025, Volume 2, No. 12
Table of Contents

Letter from the Editors

Free article

The inaugural Thomas J. Fogarty Innovation Prize celebrates the boldness, perseverance, and human impact that define the very best of medtech innovation. At its first annual gala, the award was presented to former CEO and Co-Founder Allan Zingeler and CTO Raju Viswanathan, PhD, both of FARAPULSE, and Michael Mahoney on behalf of Boston Scientific for FARAPULSE, pioneers of a breakthrough therapy that is transforming the treatment of atrial fibrillation (AFib). This spotlight explores the vision behind the Prize, the legacy of Dr. Fogarty, and the extraordinary journey of the FARAPULSE team that embodies the award's purpose.

Free article

Flow Medical Co-Founder and CEO Jennifer Fried is leading one of the most closely watched developments in pulmonary embolism (PE) treatment, bringing precision medicine principles into a space long limited by guesswork. Backed by expert clinical founders and growing momentum from clinicians and investors, the company is preparing for major preclinical and regulatory milestones. With a next-generation catheter designed to personalize lytic dosing in real time, Flow Medical is aiming to redefine how PE patients are treated.

Need fresh inspiration for your medtech company as we enter Q126? We've gathered insights from some of our LSI alumni thought leaders to help you stay ahead.

Celebrating recent leadership shifts and other announcements and accolades impacting our global LSI Alumni medtech community.

Select Medtech Industry Financings & Deals: November 2025, by Date Announced

Spotlighting capital partners who continue to drive innovation across medtech

An unexpected partnership is helping define the next generation of need-driven healthcare innovation. Nina Capital's founder, Marta Zanchi, PhD, and Methinks AI CEO, Pau Rodriguez, are showing how carefully applied information technology and AI can change patient care at scale, when the right people focus on the right problems.

Embolization agents are a cornerstone of interventional oncology, playing a vital role in tumor treatment through targeted vessel occlusion. As adoption of embolization techniques rises across oncology and peripheral interventions, the global market is accelerating with it. Growth is being fueled by a combination of rising cancer incidence, broader clinical adoption, and innovation in embolic technologies.

Some of the most active investment firms in medtech, based on recent deal history from our Compass AI platform and proprietary insights from LSI Emerging Medtech Summits in the USA, Europe, and Asia.

Every week, LSI's Market Intelligence team tracks the signals shaping global medtech. November brought three major themes across the data: accelerating innovation in cardiovascular devices, strong performance from the industry's largest strategics during Q3 earnings season, and another surge in medtech M&A activity. Taken together, the numbers point to a market that remains highly active, strategically focused, and positioned for continued momentum heading into 2026.

U.S. vs EU: Procedure Volumes, by Indication, 2023–2030

Global Heart Failure Procedure Volumes, by Type, 2024–2031

Celebrating the accomplishments of a few of the many bright stars in our LSI presenting company and speaker alumni community.

This month, we're showcasing technologies and organizations impacting our industry and patient lives.

Trusted By The Companies Pioneering What’s Next

Work with us
Accelerate your business
We’re here to help you make smarter decisions and form stronger
partnerships through curated events, independent market intelligence
products and services, and digital-forward media.